Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
Iversen L, Conrad C, Eidsmo L, Costanzo A, Narbutt J, Pinter A, Kingo K, Rivera Diaz R, Kolbinger F, Nanna M, Frueh JA, Jagiello P. Iversen L, et al. Among authors: jagiello p. J Eur Acad Dermatol Venereol. 2023 May;37(5):1004-1016. doi: 10.1111/jdv.18846. Epub 2023 Jan 27. J Eur Acad Dermatol Venereol. 2023. PMID: 36606536 Clinical Trial.
Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
Augustin M, Sator PG, von Kiedrowski R, Conrad C, Rigopoulos D, Romanelli M, Ghislain PD, Torres T, Ioannides D, Aassi M, Schulz B, Jagiello P; SERENA study group. Augustin M, et al. Among authors: jagiello p. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1796-1804. doi: 10.1111/jdv.18329. Epub 2022 Jul 4. J Eur Acad Dermatol Venereol. 2022. PMID: 35696305
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab.
Kiltz U, Sfikakis PP, Gaffney K, Bounas A, Gullick N, Lespessailles E, Brandt-Juergens J, Rashkov R, Schulz B, Pournara E, Jagiello P. Kiltz U, et al. Among authors: jagiello p. Rheumatol Ther. 2022 Aug;9(4):1129-1142. doi: 10.1007/s40744-022-00460-x. Epub 2022 Jun 8. Rheumatol Ther. 2022. PMID: 35674938 Free PMC article.
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Gottlieb AB, Deodhar A, Mcinnes IB, Baraliakos X, Reich K, Schreiber S, Bao W, Marfo K, Richards HB, Pricop L, Shete A, Trivedi V, Keefe D, Papavassilis CC, Jagiello P, Papanastasiou P, Mease PJ, Lebwohl M. Gottlieb AB, et al. Among authors: jagiello p. Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563. Acta Derm Venereol. 2022. PMID: 35146532 Free PMC article.
Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.
Foley P, Tsai TF, Rodins K, Hamadah IR, Ammoury A, Dayem HA, Abdallah M, Crowe S, Haas S, Pournara E, Jagiello P, Huang YH. Foley P, et al. Among authors: jagiello p. Dermatol Ther (Heidelb). 2022 Feb;12(2):511-527. doi: 10.1007/s13555-021-00675-w. Epub 2022 Jan 17. Dermatol Ther (Heidelb). 2022. PMID: 35038128 Free PMC article.
Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study.
da Silva N, Sommer R, Ortmann CE, Jagiello P, Bachhuber T, Augustin M. da Silva N, et al. Among authors: jagiello p. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2241-2249. doi: 10.1111/jdv.17525. Epub 2021 Jul 31. J Eur Acad Dermatol Venereol. 2021. PMID: 34273904
Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, Szepietowski JC, Perrot JL, Cuccia A, Rissler M, Gathmann S, Sieder C, Orsenigo R, Jagiello P, Bachhuber T. Augustin M, et al. Among authors: jagiello p. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):431-440. doi: 10.1111/jdv.16632. Epub 2020 Jul 1. J Eur Acad Dermatol Venereol. 2021. PMID: 32426889
36 results